Forget Nvidia: 3 Prominent Billionaire Investors Are Selling It and Buying These 6 Value Stocks InsteadThe Motley Fool • 04/08/24
New Pharmacokinetic Modeling Data Presented by Teva Simulates Clinical Profiles of Schizophrenia Patients Switching to UZEDY® (risperidone) Extended-Release Injectable Suspension at SIRS 2024Business Wire • 04/06/24
Teva and mAbxience Announce Strategic Global Licensing Agreement for Oncology Biosimilar CandidateBusiness Wire • 04/04/24
Teva UK and Closed Loop Medicine Announce Strategic Partnership to Advance Development of Personalised MedicinesBusiness Wire • 03/26/24
Teva and Jiangsu Nhwa Forge Strategic Partnership to Promote Patient Access to AUSTEDO® in ChinaBusiness Wire • 02/26/24
Teva Presents New Data Supporting Safety, Tolerability and Target Engagement of Anti-TL1A (TEV-‘574) Antibody at the 2024 ECCO Annual MeetingBusiness Wire • 02/20/24
Teva Canada Named by Forbes as No. 1 Canadian Employer in Drugs & Biotechnology IndustryBusiness Wire • 02/07/24
MedinCell's Partner Teva Provides Guidance for UZEDY in 2024 and an Update on the Treatment-Candidate of Olanzapine Long-Acting Injectable (LAI)Business Wire • 01/31/24
Teva Pharmaceutical Industries Ltd. (TEVA) Q4 Earnings: Taking a Look at Key Metrics Versus EstimatesZacks Investment Research • 01/31/24
Teva Sinks On Lackluster Profit Outlook Despite Walloping Quarterly ProjectionsInvestors Business Daily • 01/31/24
Teva Announces Intention to Divest API Business as Part of Pivot to Growth StrategyBusiness Wire • 01/31/24
Unveiling Teva Pharmaceutical Industries Ltd. (TEVA) Q4 Outlook: Wall Street Estimates for Key MetricsZacks Investment Research • 01/26/24
Why Big Pharma Led By Merck, Sanofi, Teva Are Pouring Billions Into A New Immunology SpaceInvestors Business Daily • 01/12/24